Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome

S. Barrio, T. D. Shanafelt, J. Ojha, K. G. Chaffee, C. Secreto, K. M. Kortüm, S. Pathangey, D. L. Van-Dyke, Susan L Slager, Rafael Fonseca, Neil Elliot Kay, Esteban D Braggio

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

High-count monoclonal B-cell lymphocytosis (MBL) is an asymptomatic expansion of clonal B cells in the peripheral blood without other manifestations of chronic lymphocytic leukemia (CLL). Yearly, 1% of MBLs evolve to CLL requiring therapy; thus being critical to understand the biological events that determine which MBLs progress to intermediate/advanced CLL. In this study, we performed targeted deep sequencing on 48 high-count MBLs, 47 of them with 2–4 sequential samples analyzed, exploring the mutation status of 21 driver genes and evaluating clonal evolution. We found somatic non-synonymous mutations in 25 MBLs (52%) at the initial time point analyzed, including 12 (25%) with >1 mutated gene. In cases that subsequently progressed to CLL, mutations were detected 41 months (median) prior to progression. Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum. MBLs with mutations at the initial time point analyzed were associated with shorter time-to-treatment (TTT). Furthermore, MBLs showing subclonal expansion of driver mutations on sequential evaluation had shorter progression time to CLL and shorter TTT. These findings support that clonal evolution has prognostic implications already at the pre-malignant MBL stage, anticipating which individuals will progress earlier to CLL.Leukemia advance online publication, 29 July 2016; doi:10.1038/leu.2016.172.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jul 29 2016

Fingerprint

Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Mutation
Clonal Evolution
Genes
High-Throughput Nucleotide Sequencing
Publications
Leukemia
Incidence

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. / Barrio, S.; Shanafelt, T. D.; Ojha, J.; Chaffee, K. G.; Secreto, C.; Kortüm, K. M.; Pathangey, S.; Van-Dyke, D. L.; Slager, Susan L; Fonseca, Rafael; Kay, Neil Elliot; Braggio, Esteban D.

In: Leukemia, 29.07.2016.

Research output: Contribution to journalArticle

@article{374e1b707ccd40689ac953b4ffe53cfe,
title = "Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome",
abstract = "High-count monoclonal B-cell lymphocytosis (MBL) is an asymptomatic expansion of clonal B cells in the peripheral blood without other manifestations of chronic lymphocytic leukemia (CLL). Yearly, 1{\%} of MBLs evolve to CLL requiring therapy; thus being critical to understand the biological events that determine which MBLs progress to intermediate/advanced CLL. In this study, we performed targeted deep sequencing on 48 high-count MBLs, 47 of them with 2–4 sequential samples analyzed, exploring the mutation status of 21 driver genes and evaluating clonal evolution. We found somatic non-synonymous mutations in 25 MBLs (52{\%}) at the initial time point analyzed, including 12 (25{\%}) with >1 mutated gene. In cases that subsequently progressed to CLL, mutations were detected 41 months (median) prior to progression. Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum. MBLs with mutations at the initial time point analyzed were associated with shorter time-to-treatment (TTT). Furthermore, MBLs showing subclonal expansion of driver mutations on sequential evaluation had shorter progression time to CLL and shorter TTT. These findings support that clonal evolution has prognostic implications already at the pre-malignant MBL stage, anticipating which individuals will progress earlier to CLL.Leukemia advance online publication, 29 July 2016; doi:10.1038/leu.2016.172.",
author = "S. Barrio and Shanafelt, {T. D.} and J. Ojha and Chaffee, {K. G.} and C. Secreto and Kort{\"u}m, {K. M.} and S. Pathangey and Van-Dyke, {D. L.} and Slager, {Susan L} and Rafael Fonseca and Kay, {Neil Elliot} and Braggio, {Esteban D}",
year = "2016",
month = "7",
day = "29",
doi = "10.1038/leu.2016.172",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome

AU - Barrio, S.

AU - Shanafelt, T. D.

AU - Ojha, J.

AU - Chaffee, K. G.

AU - Secreto, C.

AU - Kortüm, K. M.

AU - Pathangey, S.

AU - Van-Dyke, D. L.

AU - Slager, Susan L

AU - Fonseca, Rafael

AU - Kay, Neil Elliot

AU - Braggio, Esteban D

PY - 2016/7/29

Y1 - 2016/7/29

N2 - High-count monoclonal B-cell lymphocytosis (MBL) is an asymptomatic expansion of clonal B cells in the peripheral blood without other manifestations of chronic lymphocytic leukemia (CLL). Yearly, 1% of MBLs evolve to CLL requiring therapy; thus being critical to understand the biological events that determine which MBLs progress to intermediate/advanced CLL. In this study, we performed targeted deep sequencing on 48 high-count MBLs, 47 of them with 2–4 sequential samples analyzed, exploring the mutation status of 21 driver genes and evaluating clonal evolution. We found somatic non-synonymous mutations in 25 MBLs (52%) at the initial time point analyzed, including 12 (25%) with >1 mutated gene. In cases that subsequently progressed to CLL, mutations were detected 41 months (median) prior to progression. Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum. MBLs with mutations at the initial time point analyzed were associated with shorter time-to-treatment (TTT). Furthermore, MBLs showing subclonal expansion of driver mutations on sequential evaluation had shorter progression time to CLL and shorter TTT. These findings support that clonal evolution has prognostic implications already at the pre-malignant MBL stage, anticipating which individuals will progress earlier to CLL.Leukemia advance online publication, 29 July 2016; doi:10.1038/leu.2016.172.

AB - High-count monoclonal B-cell lymphocytosis (MBL) is an asymptomatic expansion of clonal B cells in the peripheral blood without other manifestations of chronic lymphocytic leukemia (CLL). Yearly, 1% of MBLs evolve to CLL requiring therapy; thus being critical to understand the biological events that determine which MBLs progress to intermediate/advanced CLL. In this study, we performed targeted deep sequencing on 48 high-count MBLs, 47 of them with 2–4 sequential samples analyzed, exploring the mutation status of 21 driver genes and evaluating clonal evolution. We found somatic non-synonymous mutations in 25 MBLs (52%) at the initial time point analyzed, including 12 (25%) with >1 mutated gene. In cases that subsequently progressed to CLL, mutations were detected 41 months (median) prior to progression. Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum. MBLs with mutations at the initial time point analyzed were associated with shorter time-to-treatment (TTT). Furthermore, MBLs showing subclonal expansion of driver mutations on sequential evaluation had shorter progression time to CLL and shorter TTT. These findings support that clonal evolution has prognostic implications already at the pre-malignant MBL stage, anticipating which individuals will progress earlier to CLL.Leukemia advance online publication, 29 July 2016; doi:10.1038/leu.2016.172.

UR - http://www.scopus.com/inward/record.url?scp=84979995657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979995657&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.172

DO - 10.1038/leu.2016.172

M3 - Article

C2 - 27469216

AN - SCOPUS:84979995657

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -